A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients with Relapsed High-Risk Multiple Myeloma
The purpose of this study is to test the safety of the study drug (also called Ixazomib or MLN 9708) given after a specific chemotherapy regimen and donor stem cell transplant. We want to find out what effects, good and/or bad, the study drug has on you and your cancer after transplant. Another purpose of the study is to evaluate the efficacy (or lack of efficacy) of the overall transplant followed by treatment with the study drug.
-Patients with relapsed or newly diagnosed Mutiple Myeloma that meets criteria as determined by the study investigator.
-Patients with Plasma Cell Leukemia that meets certain criteria as determined by the investigator.
-Patient must have an available sibling or matched related stem cell donor. (Patients who have previously received a sibling or unrelated donor stem cell transplant are excluded.)
-Other criteria as determined by the investigator.
18 - 65
Healthy Volunteers Needed
Duration of Participation
-Patient may take study drug for up to about 2 years after transplant.
-Patient may continue long-term study follow-up for an additional 2 years after stopping study drug.
Knight Clinical Trials Office Information Line
Emma Scott, MD